ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Gentofte Hospital (Copenhagen University Hospital Gentofte) is located in Gentofte within Copenhagen in Denmark. Administratively, it is part of the hospital service of Region Hovedstaden. The hospital primarily serves the municipalities of Gentofte, Lyngby-Taarbæk, and Rudersdal, with a population of about 175,000.

Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.

Rigshospitalet (meaning The National, State or Kingdom Hospital, but not usually translated) is one of the largest hospitals in Denmark and the most highly specialised hospital in Copenhagen. The hospital's main building is a 16 storey functionalist highrise, one of the tallest structures in the central parts of the city. Rigshospitalet neighbours the Panum Building which houses the Faculty of Health and Medical Sciences at the University of Copenhagen. As a teaching hospital it is part of the framework organisation Copenhagen University Hospital.

RaQualia began operations in July 2008 with a corporate mission, "They seek to bring people health and happiness through innovative new medications." Thanks to the support of all of their stakeholders, the company was listed on the JASDAQ Growth Market in July 2011. They have transformed RaQualia's R&D strategy, which is now based on the concept of "selection and concentration." They are now focusing on their core competencies in targeting ion channels in the fields of pain and gastrointestinal disease. In addition, they have made a strategic decision to relocate RaQualia's discovery processes to Nagoya University to better promote synergy effects with academia. With the Chubu region as their base, they are continuing with further efforts enhance their capabilities in drug discovery, improve shareholder value, and achieve financial stability by promoting licensing activities and alliance management with their corporate partners. They will continue to work tirelessly in providing patients with innovative medicines sooner by increasing the pace of drug development. Thank you very much for your continued support of RaQualia.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Astellas US LLC, part of Astellas Pharma, Inc., is an American company located in Northbrook, IL. The firm manufactures and markets pharmaceutical products. Kenji Yasukawa is the current CEO of the firm.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA.

Privately held biotechnology company developing protein therapeutics that address unmet clinical and societal needs in the areas of Oncology, Hematology and Immunology

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

DermTech develops and commercializes qPCR assays for skin samples collected non-invasively using adhesive tape biopsy methods. The Company’s assays can analyze multiple gene targets to assess their level of RNA expression. The Company anticipates providing these assays through a CLIA certified laboratory located in San Diego. The Company will initially offer an assay for pigmented skin lesions sampled using an adhesive tape collection method. The Company has identified gene targets differentially expressed in melanoma samples (British Journal of Dermatology, April 2011). This assay can assess RNA expression consistent with melanoma with very high sensitivity (>95%) and specificity (>70%).

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Incyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. Incyte's product pipeline is currently focused on oncology and inflammation and includes compounds in various stages of development. Through partnerships with [Novartis](/organization/novartis), [Eli Lilly](/organization/eli-lilly), and [Pfizer](/organization/pfizer), Incyte intends to promote the clinical development and global commercialization of several of their compounds.

ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.